| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.786 | 0.003 | 0.786 | DNA synthesis inhibitor | 0.624 0.007 DBMET02516 0.718 0.004 DBMET02517 0.631 0.006 DBMET02518 0.531 0.011 DBMET02515 | ||
| 0.697 | 0.009 | 0.779 | Antibacterial | 0.733 0.006 DBMET02516 0.706 0.008 DBMET02517 0.779 0.004 DBMET02518 0.653 0.013 DBMET02515 | DBMET02518 | |
| 0.641 | 0.004 | 0.641 | Topoisomerase II inhibitor | 0.585 0.005 DBMET02516 0.605 0.005 DBMET02517 0.484 0.007 DBMET02518 0.602 0.005 DBMET02515 | ||
| 0.62 | 0.001 | 0.62 | Topoisomerase II beta inhibitor | 0.383 0.002 DBMET02516 0.495 0.001 DBMET02517 0.258 0.003 DBMET02518 0.378 0.002 DBMET02515 | ||
| 0.406 | 0.003 | 0.406 | DNA gyrase inhibitor | 0.329 0.004 DBMET02516 0.341 0.004 DBMET02517 0.247 0.004 DBMET02518 0.246 0.004 DBMET02515 | ||
| 0.344 | 0.002 | 0.344 | DNA topoisomerase IV inhibitor | 0.275 0.003 DBMET02516 0.277 0.003 DBMET02517 0.16 0.003 DBMET02518 0.159 0.003 DBMET02515 | ||
| 0.323 | 0.038 | 0.323 | Interleukin agonist | 0.215 0.107 DBMET02516 0.261 0.071 DBMET02517 | ||
| 0.275 | 0.003 | 0.275 | DNA gyrase subunit B inhibitor | 0.154 0.004 DBMET02516 0.185 0.003 DBMET02517 0.037 0.027 DBMET02518 0.092 0.005 DBMET02515 | ||
| 0.251 | 0.016 | 0.406 | Cell wall synthesis inhibitor | 0.331 0.008 DBMET02516 0.24 0.018 DBMET02517 0.406 0.006 DBMET02518 0.226 0.022 DBMET02515 | DBMET02518 | |
| 0.294 | 0.068 | 0.373 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.373 0.028 DBMET02516 0.276 0.083 DBMET02517 0.303 0.062 DBMET02515 | DBMET02516 | |
| 0.19 | 0.002 | 0.19 | DNA gyrase subunit A inhibitor | 0.165 0.002 DBMET02516 0.167 0.002 DBMET02517 0.138 0.003 DBMET02518 0.142 0.003 DBMET02515 | ||
| 0.189 | 0.029 | 0.25 | Topoisomerase I inhibitor | 0.25 0.017 DBMET02516 0.168 0.035 DBMET02517 0.169 0.035 DBMET02515 | DBMET02516 | |
| 0.165 | 0.037 | 0.262 | DNA intercalator | 0.095 0.079 DBMET02516 0.139 0.048 DBMET02517 0.262 0.015 DBMET02515 | DBMET02515 | |
| 0.224 | 0.097 | 0.346 | DNA damaging | 0.346 0.042 DBMET02515 | DBMET02515 | |
| 0.15 | 0.034 | 0.169 | GABA C receptor agonist | 0.169 0.028 DBMET02515 | DBMET02515 | |
| 0.114 | 0.014 | 0.133 | Protein kinase C eta inhibitor | 0.049 0.045 DBMET02516 0.133 0.01 DBMET02517 0.119 0.013 DBMET02515 | DBMET02517 | |
| 0.132 | 0.032 | 0.132 | Acetylcholine agonist | 0.084 0.062 DBMET02516 0.079 0.067 DBMET02517 | ||
| 0.13 | 0.031 | 0.13 | Protein kinase C delta inhibitor | 0.105 0.048 DBMET02517 0.112 0.043 DBMET02515 | ||
| 0.218 | 0.12 | 0.218 | 5 Hydroxytryptamine uptake stimulant | 0.206 0.14 DBMET02515 | ||
| 0.275 | 0.18 | 0.416 | Calcium channel L-type activator | 0.416 0.071 DBMET02517 0.262 0.193 DBMET02515 | DBMET02517 | |
| 0.122 | 0.031 | 0.132 | Protein kinase C zeta inhibitor | 0.101 0.049 DBMET02517 0.132 0.026 DBMET02515 | DBMET02515 | |
| 0.099 | 0.01 | 0.099 | Cyclin-dependent kinase 6 inhibitor | 0.081 0.021 DBMET02517 | ||
| 0.181 | 0.093 | 0.299 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.197 0.079 DBMET02517 0.299 0.037 DBMET02515 | DBMET02515 | |
| 0.22 | 0.135 | 0.22 | Nootropic | 0.21 0.145 DBMET02517 | ||
| 0.104 | 0.023 | 0.104 | HIV-1 integrase inhibitor | 0.077 0.041 DBMET02516 0.098 0.026 DBMET02517 0.081 0.037 DBMET02518 0.077 0.04 DBMET02515 | ||
| 0.092 | 0.018 | 0.092 | Protein kinase C beta inhibitor | 0.082 0.028 DBMET02517 0.071 0.046 DBMET02515 | ||
| 0.13 | 0.059 | 0.13 | 5 Hydroxytryptamine antagonist | 0.128 0.061 DBMET02516 | ||
| 0.14 | 0.071 | 0.294 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.11 0.092 DBMET02517 0.294 0.02 DBMET02515 | DBMET02515 | |
| 0.079 | 0.011 | 0.079 | 5 Hydroxytryptamine 2C agonist | |||
| 0.09 | 0.023 | 0.09 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.122 | 0.054 | 0.122 | 5 Hydroxytryptamine 3A agonist | |||
| 0.191 | 0.127 | 0.191 | Superoxide dismutase inhibitor | 0.171 0.155 DBMET02515 | ||
| 0.22 | 0.157 | 0.263 | Interleukin 2 agonist | 0.216 0.163 DBMET02517 0.263 0.105 DBMET02515 | DBMET02515 | |
| 0.1 | 0.046 | 0.1 | Pim-3 kinase inhibitor | 0.086 0.064 DBMET02517 | ||
| 0.137 | 0.085 | 0.212 | Hemostatic | 0.155 0.062 DBMET02517 0.212 0.028 DBMET02515 | DBMET02515 | |
| 0.156 | 0.107 | 0.355 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.138 0.125 DBMET02516 0.136 0.128 DBMET02517 0.355 0.027 DBMET02515 | DBMET02515 | |
| 0.079 | 0.036 | 0.079 | Cyclin-dependent kinase 4 inhibitor | 0.061 0.051 DBMET02516 0.063 0.048 DBMET02517 | ||
| 0.139 | 0.097 | 0.262 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.13 0.105 DBMET02517 0.262 0.042 DBMET02515 | DBMET02515 | |
| 0.079 | 0.039 | 0.156 | Cyclin B3 inhibitor | 0.156 0.012 DBMET02516 0.064 0.051 DBMET02517 | DBMET02516 | |
| 0.083 | 0.043 | 0.083 | Alpha 1a adrenoreceptor antagonist | |||
| 0.044 | 0.005 | 0.044 | Protein kinase C beta I inhibitor | 0.038 0.012 DBMET02516 0.042 0.007 DBMET02517 0.033 0.023 DBMET02518 0.035 0.018 DBMET02515 | ||
| 0.087 | 0.049 | 0.087 | Alpha 1 adrenoreceptor antagonist | |||
| 0.067 | 0.03 | 0.089 | 5 Hydroxytryptamine 3 antagonist | 0.089 0.021 DBMET02516 | DBMET02516 | |
| 0.076 | 0.04 | 0.076 | Phospholipase D inhibitor | 0.07 0.053 DBMET02517 | ||
| 0.085 | 0.051 | 0.085 | Acetylcholine nicotinic agonist | |||
| 0.096 | 0.064 | 0.096 | Creatine kinase inhibitor | |||
| 0.06 | 0.028 | 0.06 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.039 | 0.012 | 0.039 | Protein kinase C beta II inhibitor | 0.036 0.016 DBMET02517 0.034 0.02 DBMET02515 | ||
| 0.035 | 0.008 | 0.035 | DNA polymerase III inhibitor | 0.029 0.017 DBMET02516 0.033 0.01 DBMET02517 | ||
| 0.099 | 0.072 | 0.126 | 5 Hydroxytryptamine 2 antagonist | 0.126 0.055 DBMET02516 | DBMET02516 | |
| 0.07 | 0.044 | 0.07 | Acetylcholine M5 receptor agonist | |||
| 0.057 | 0.031 | 0.068 | Autotaxin inhibitor | 0.049 0.043 DBMET02516 0.068 0.024 DBMET02518 | DBMET02518 | |
| 0.09 | 0.067 | 0.129 | Protein kinase C mu inhibitor | 0.129 0.037 DBMET02517 | DBMET02517 | |
| 0.099 | 0.078 | 0.146 | Protein kinase C gamma inhibitor | 0.146 0.034 DBMET02515 | DBMET02515 | |
| 0.067 | 0.049 | 0.067 | 5 Hydroxytryptamine agonist | |||
| 0.066 | 0.049 | 0.066 | Protein kinase C alpha inhibitor | 0.064 0.053 DBMET02517 | ||
| 0.088 | 0.07 | 0.088 | Pim-1 kinase inhibitor | |||
| 0.058 | 0.041 | 0.058 | CDK4/cyclin D1 inhibitor | 0.055 0.043 DBMET02517 | ||
| 0.042 | 0.026 | 0.042 | Acid-sensing ion channel blocker | |||
| 0.059 | 0.044 | 0.059 | Cyclin D1 inhibitor | |||
| 0.078 | 0.063 | 0.078 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.018 | 0.004 | 0.018 | DNA polymerase III polC-type inhibitor | 0.016 0.005 DBMET02516 0.017 0.004 DBMET02517 0.014 0.008 DBMET02518 0.013 0.012 DBMET02515 | ||
| 0.04 | 0.027 | 0.072 | Cyclin D3 inhibitor | 0.072 0.012 DBMET02516 | DBMET02516 | |
| 0.06 | 0.047 | 0.06 | 5 Hydroxytryptamine 2A agonist | |||
| 0.096 | 0.085 | 0.109 | Multidrug resistance-associated protein 1 inhibitor | 0.109 0.064 DBMET02515 | DBMET02515 | |
| 0.121 | 0.11 | 0.124 | Insulin secretagoues | 0.124 0.105 DBMET02517 | DBMET02517 | |
| 0.055 | 0.045 | 0.055 | CDK4/cyclin D inhibitor | 0.055 0.047 DBMET02517 | ||
| 0.245 | 0.236 | 0.36 | 5 Hydroxytryptamine release inhibitor | 0.36 0.107 DBMET02515 | DBMET02515 | |
| 0.038 | 0.031 | 0.038 | Nicotinic acid receptor 1 agonist | 0.036 0.035 DBMET02517 | ||
| 0.074 | 0.067 | 0.074 | Acetylcholine M3 receptor agonist | |||
| 0.205 | 0.203 | 0.205 | Antiobesity | |||
| 0.135 | 0.133 | 0.177 | Angiogenesis stimulant | 0.177 0.107 DBMET02518 | DBMET02518 | |
| 0.076 | 0.075 | 0.076 | Alpha adrenoreceptor antagonist | |||
| 0.045 | 0.047 | 0.073 | Protein kinase C epsilon inhibitor | 0.053 0.038 DBMET02517 0.073 0.023 DBMET02515 | DBMET02515 | |
| 0.087 | 0.09 | 0.196 | Protein kinase (CK2) alpha inhibitor | 0.196 0.025 DBMET02515 | DBMET02515 | |
| 0.061 | 0.065 | 0.068 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.068 0.055 DBMET02516 | DBMET02516 | |
| 0.015 | 0.022 | 0.023 | Nociceptin (N/OFQ) receptor agonist | 0.023 0.013 DBMET02517 | DBMET02517 | |
| 0.045 | 0.055 | 0.067 | Glutamate (mGluR1) antagonist | 0.067 0.032 DBMET02517 0.065 0.034 DBMET02515 | DBMET02517 | |
| 0.077 | 0.087 | 0.158 | Protein kinase (CK2) inhibitor | 0.158 0.029 DBMET02515 | DBMET02515 | |
| 0.093 | 0.105 | 0.118 | Glutamate receptor antagonist | 0.118 0.076 DBMET02515 | DBMET02515 | |
| 0.043 | 0.059 | 0.114 | Phosphodiesterase 7A inhibitor | 0.114 0.004 DBMET02516 0.054 0.032 DBMET02517 | DBMET02516 | |
| 0.059 | 0.077 | 0.1 | 5 Hydroxytryptamine 2A antagonist | 0.1 0.047 DBMET02516 | DBMET02516 | |
| 0.066 | 0.087 | 0.128 | NMDA receptor antagonist | 0.128 0.032 DBMET02515 | DBMET02515 | |
| 0.256 | 0.277 | 0.292 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.292 0.224 DBMET02515 | DBMET02515 | |
| 0.113 | 0.138 | 0.149 | Polo-like kinase-3 inhibitor | 0.136 0.102 DBMET02517 0.149 0.086 DBMET02515 | DBMET02515 | |
| 0.043 | 0.071 | 0.152 | Phosphodiesterase VII inhibitor | 0.152 0.004 DBMET02516 0.059 0.048 DBMET02517 | DBMET02516 | |
| 0.051 | 0.081 | 0.094 | Polo-like kinase-2 inhibitor | 0.094 0.031 DBMET02517 | DBMET02517 | |
| 0.063 | 0.095 | 0.095 | MAP-kinase-activated kinase inhibitor | 0.095 0.044 DBMET02517 | DBMET02517 | |
| 0.094 | 0.134 | 0.214 | Protein kinase C nu inhibitor | 0.214 0.042 DBMET02515 | DBMET02515 | |
| 0.105 | 0.152 | 0.149 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.149 0.096 DBMET02515 | DBMET02515 | |
| 0.039 | 0.086 | 0.054 | Cyclin B1 inhibitor | 0.054 0.051 DBMET02516 | DBMET02516 | |
| 0.032 | 0.086 | 0.051 | Cyclin B2 inhibitor | 0.051 0.045 DBMET02516 | DBMET02516 | |
| 0.112 | 0.166 | 0.293 | MAP kinase kinase 2 inhibitor | 0.293 0.038 DBMET02515 | DBMET02515 | |
| 0.048 | 0.108 | 0.077 | MAP-kinase-activated kinase 2 inhibitor | 0.077 0.048 DBMET02517 | DBMET02517 | |
| 0.063 | 0.138 | 0.082 | Polo-like kinase-1 inhibitor | 0.082 0.08 DBMET02515 | DBMET02515 | |
| 0.084 | 0.168 | 0.117 | Antibacterial (Helicobacter pylori) | 0.117 0.086 DBMET02518 | DBMET02518 | |
| 0.03 | 0.116 | 0.047 | Dopamine beta hydroxylase inhibitor | 0.047 0.038 DBMET02515 | DBMET02515 | |
| 0.088 | 0.187 | 0.145 | TRKC antagonist | 0.145 0.105 DBMET02515 | DBMET02515 | |
| 0.052 | 0.16 | 0.088 | Aminoacyl-tRNA synthetase inhibitor | 0.088 0.063 DBMET02515 | DBMET02515 | |
| 0.098 | 0.207 | 0.169 | I kappa B kinase epsilon inhibitor | 0.169 0.1 DBMET02516 | DBMET02516 | |
| 0.1 | 0.221 | 0.158 | Platelet antagonist | 0.158 0.136 DBMET02517 | DBMET02517 | |
| 0.082 | 0.223 | 0.214 | Heat shock protein 90 alpha antagonist | 0.214 0.041 DBMET02516 | DBMET02516 | |
| 0.009 | 0.15 | 0.034 | Kinesin antagonist | 0.034 0.03 DBMET02515 | DBMET02515 | |
| 0.009 | 0.15 | 0.034 | Kinesin-like protein 1 inhibitor | 0.034 0.03 DBMET02515 | DBMET02515 | |
| 0.055 | 0.198 | 0.092 | MAP kinase kinase 1 inhibitor | 0.092 0.067 DBMET02515 | DBMET02515 | |
| 0.076 | 0.225 | 0.143 | MAP3K9 inhibitor | 0.143 0.072 DBMET02517 | DBMET02517 | |
| 0.053 | 0.208 | 0.13 | MAP kinase kinase inhibitor | 0.13 0.065 DBMET02515 | DBMET02515 | |
| 0.04 | 0.2 | 0.162 | Polo-like kinase-4 inhibitor | 0.162 0.029 DBMET02517 | DBMET02517 | |
| 0.025 | 0.198 | 0.06 | Protein kinase C iota inhibitor | 0.06 0.041 DBMET02515 | DBMET02515 | |
| 0.032 | 0.233 | 0.071 | Somatostatin 1 agonist | 0.071 0.063 DBMET02515 | DBMET02515 | |
| 0.039 | 0.251 | 0.1 | Chelator | 0.1 0.078 DBMET02515 | DBMET02515 | |
| 0.025 | 0.237 | 0.07 | Parathyroid hormone antagonist | 0.07 0.007 DBMET02515 | DBMET02515 | |
| 0.062 | 0.276 | 0.172 | Heat shock protein 90 antagonist | 0.172 0.054 DBMET02516 | DBMET02516 | |
| 0.115 | 0.336 | 0.165 | MAP kinase kinase 5 inhibitor | 0.165 0.099 DBMET02515 | DBMET02515 | |
| 0.005 | 0.234 | 0.068 | Urotensin II antagonist | 0.068 0.005 DBMET02518 | DBMET02518 | |
| 0.042 | 0.272 | 0.122 | Protein kinase (CK1) gamma inhibitor | 0.122 0.088 DBMET02515 | DBMET02515 | |
| 0.068 | 0.299 | 0.175 | Death-associated protein kinase 3 inhibitor | 0.175 0.092 DBMET02515 | DBMET02515 | |
| 0.029 | 0.276 | 0.079 | Telomerase inhibitor | 0.079 0.045 DBMET02515 | DBMET02515 | |
| 0.046 | 0.306 | 0.162 | Protein kinase (CK1) gamma 1 inhibitor | 0.162 0.06 DBMET02515 | DBMET02515 | |
| 0.038 | 0.325 | 0.153 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.153 0.117 DBMET02515 | DBMET02515 | |
| 0.032 | 0.321 | 0.203 | Antineoplastic alkaloid | 0.203 0.013 DBMET02516 | DBMET02516 | |
| 0.041 | 0.335 | 0.14 | LIM domain kinase 1 inhibitor | 0.14 0.108 DBMET02515 | DBMET02515 | |
| 0.008 | 0.319 | 0.037 | Neurokinin 2 antagonist | 0.037 0.033 DBMET02516 | DBMET02516 | |
| 0.024 | 0.344 | 0.124 | Alkylator | 0.124 0.064 DBMET02515 | DBMET02515 | |
| 0.062 | 0.402 | 0.209 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.209 0.084 DBMET02515 | DBMET02515 | |
| 0.014 | 0.39 | 0.041 | GHS receptor agonist | 0.041 0.033 DBMET02516 | DBMET02516 | |
| 0.005 | 0.453 | 0.05 | Phosphodiesterase 3B inhibitor | 0.05 0.025 DBMET02517 | DBMET02517 | |
| 0.017 | 0.576 | 0.104 | Phosphodiesterase VIII inhibitor | 0.104 0.012 DBMET02516 | DBMET02516 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |